America and Britain Conclude Zero-Tariff Agreement on Prescription Drugs.

Britain and America have hammered out a major trade agreement that will ensure zero tariffs on UK medicine exports going into the American market.

The Terms of the Accord

In exchange for the tariff guarantee, the UK has committed to increase funding on pharmaceuticals through the public health system. This pledge secures that tariffs on these vital goods will be held at zero for a duration of three years.

This agreement is in response to earlier statements to hike duties on patented pharmaceutical imports, with figures discussed up to 100%.

"This deal between the UK strengthens the global environment for cutting-edge drugs and introduces much-needed balance to U.S.–U.K. medicine commerce," a statement said.

Economic Impact

Pharmaceuticals are one of the UK's largest exports to the America, which is easily the biggest market for major UK drugmakers.

Statistics indicate that in the 12 months to the end of last September, the UK sold drugs totaling £11.1bn to the US. This amount represented 17.4% of total UK exports in that period.

"This agreement protects jobs, stimulates funding and facilitates the UK to become a global hub for life sciences," the Business and Trade Secretary stated.

Key NHS Changes

The pact includes several specific commitments from the United Kingdom:

• Higher Cost Ceiling: The UK will lift the price threshold at which it judges new therapies to be too expensive by twenty-five percent.
• Higher Drug Budget: There is a aim to raise overall public funding on treatments from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
• Payback Limit: The amount drug companies must return to the NHS to stay within budget will be restricted at 15%. Last year, rebates topped 20%.

Broader Context

The pact takes place against a long-running tension between the sector and the British authorities over medicine costs and NHS adoption.

These tensions were exacerbated by assertions that US consumers were paying a premium for the same drugs than patients in the Britain and the EU.

Over the last 18 months, several major drug company projects in the UK have been delayed or scrapped, while multi-billion-dollar investments have been pledged toward projects in the United States.

One official stated that the NHS had to invest a greater share on medicines, noting that its expenditure on drugs had shrunk as a share of its resources over the past decade.